公开(公告)号：US20220096421A1

公开(公告)日：2022-03-31

申请号：US17418249

申请日：2020-03-05

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  Alena Alexandrovna Ivachtchenko

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  Alena Alexandrovna Ivachtchenko

IPC分类号： A61K31/277

摘要： This invention relates to the active ingredient of a pharmaceutical composition consisting of micronized monoclinic symmetry crystals (MMSCs) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl] acetyl}amino)-3-chlorophenyl]-sulfonyl}(propanoyl)azanide with an average particle diameter ≤130 μm and methods of use thereof in the treatment of Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).

公开(公告)号：US10683315B2

公开(公告)日：2020-06-16

申请号：US15744094

申请日：2017-04-07

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  ALLA CHEM, LLC ,  Alena Alexandrovna Ivachtchenko

发明人： Alexandre Vasilievich Ivachtchenko ,  Oleg Dmitrievich Mitkin

IPC分类号： A61P31/14 ,  C07F9/6558

摘要： The present invention relates to a prodrug and application thereof for the treatment of hepatitis C virus in patients.The prodrug of general formula 1, its stereoisomer, isotopically enriched analog, or crystalline or polymorphic form,

公开(公告)号：US20190233409A1

公开(公告)日：2019-08-01

申请号：US15485269

申请日：2017-04-12

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

IPC分类号： C07D471/04 ,  A61P3/14

CPC分类号： C07D471/04 ,  A61P3/14

摘要： The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof wherein R1 is C1-C5 alkyl; R2, is independently hydrogen, halogen, C1-C3 alkyl, CF3, OCF3 or OCH3; i is 1, 2,3, or 4; Ar is unsubstituted phenyl or substituted phenyl substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, a substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle one or, with two nitrogen atoms in the heterocycle; excluding the compounds of the formulas A1-A4 The invention relates to the novel chemical compounds, methods for their preparation and use as antagonists of 5-HT6 receptors, simultaneously regulating homeostasis of calcium ions in cells. The invention relates to the novel annelated azaheterocycles—2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, to methods for their preparation, to pharmaceutical compositions, including these compounds as active substances, and to methods of treatment and profylaxis of various diseases.

公开(公告)号：US20230310467A1

公开(公告)日：2023-10-05

申请号：US17709609

申请日：2022-03-31

申请人： Alexandre Vasilievich Ivachtchenko ,  Alena Alexandrovna Ivachtchenko ,  Nikolay Filippovich Savchuk ,  ASAVI LLC

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Alena Alexandrovna Ivachtchenko ,  Ilya Andreevich Ivashchenko ,  Nikolay Filippovich Savchuk

IPC分类号： A61K31/675 ,  A61K31/519 ,  A61K38/57 ,  A61P31/14

CPC分类号： A61K31/675 ,  A61K31/519 ,  A61K38/57 ,  A61P31/14

摘要： The application relates to pharmaceutical combinations, methods, and therapies for the treatment and prevention of SARS-CoV-2 infection and related diseases. The combinations contain aprotinin, baricitinib, and/or remdesivir. The application also includes related pharmaceutical kits. Further details are described in the specification.

公开(公告)号：US20230020329A1

公开(公告)日：2023-01-19

申请号：US17432115

申请日：2020-03-05

申请人： Alexandrovna Alena Ivachtchenko ,  Alexandre Vasilievich Ivachtchenko ,  Nikolay Filippovich Savchuk ,  Andrey Alexandrovich Ivashchenko

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  Oleg Dmitrievich Mitkin

IPC分类号： C07D498/14

摘要： The present invention relates to a novel compound that has antiviral activity, in particular, inhibitory activity against the integrase of the human immunodeficiency virus (HIV).
The subject of this invention is a novel annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamide of general formula 1 or 2, or any stereoisomer, any pharmaceutically acceptable salt, any solvate, or any crystalline or polycrystalline form thereof wherein ring A1 is an optionally methyl-substituted 5-7 membered saturated heterocycle or heterobicycle; ring A2 is a 5-6 membered optionally methyl-substituted saturated or partially saturated monocyclic heterocycle; ring A3 is a 5-6 membered monocyclic saturated cycloalkane or tetrahydro-2H-pyran; R is a 5-7 membered optionally substituted with one, two, or three optionally identical substituents monocyclic or bicyclic heterocyclic radical comprising 1-4 heteroatoms selected from the series O, S, and N except (2S,5R,13aS)-8-hydroxy-7,9-dioxo-N-{[3-(trifluoromethyl)-pyridin-2-yl]methyl}-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopurido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (formula A4) and (1R,4S,12aR)-N-[(3,5-difluoropyridin-2-yl)methyl]-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1′,2′-d]pyrazine-9-carboxamide (formula A5).

公开(公告)号：US09790207B2

公开(公告)日：2017-10-17

申请号：US14845333

申请日：2015-09-04

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  ALLA CHEM, LLC

发明人： Alexandre Vasilievich Ivachtchenko ,  Oleg Dmitrievich Mitkin

IPC分类号： C07D403/14 ,  A61K31/4178 ,  A61K31/496 ,  C07D401/14 ,  A61K31/4439 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7056 ,  A61K38/48 ,  A61K31/427

CPC分类号： C07D403/14 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/4858 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/7056 ,  A61K38/21 ,  A61K38/482 ,  A61K45/06 ,  A61K47/10 ,  C07D401/14 ,  C12Y304/21

摘要： Compound represented by formula 1: or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: R1 is hydrogen, tert-butoxycarbonyl, where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (←) indicate the position of substituents attachment; R2 is hydrogen, halogen, or C1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (←) indicate the position of substituents attachment.

公开(公告)号：US09655886B2

公开(公告)日：2017-05-23

申请号：US14791280

申请日：2015-07-03

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

发明人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

IPC分类号： A61K31/44 ,  A61K31/437 ,  C07D471/04 ,  A61K31/444

CPC分类号： A61K31/437 ,  A61K31/444 ,  C07D471/04

摘要： The present invention relates to a method of antagonizing a 5-HT6 serotonin receptor, comprising administering to the cell a compound of formula 1.2, or a pharmaceutically acceptable salt thereof, wherein: R1 is a C1-C5 alkyl; R2i is independently hydrogen, halogen, a C1-C3 alkyl, CF3, OCF3 or OCH3; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle. The invention also relates to pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1.2 according to claim 1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20170066746A1

公开(公告)日：2017-03-09

申请号：US14845333

申请日：2015-09-04

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk ,  ALLA CHEM, LLC

发明人： Alexandre Vasilievich Ivachtchenko ,  Oleg Dmitrievich Mitkin

IPC分类号： C07D403/14 ,  A61K31/496 ,  C07D401/14 ,  A61K31/427 ,  A61K45/06 ,  A61K38/21 ,  A61K31/7056 ,  A61K38/48 ,  A61K31/4178 ,  A61K31/4439

CPC分类号： C07D403/14 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/2059 ,  A61K9/4858 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/7056 ,  A61K38/21 ,  A61K38/482 ,  A61K45/06 ,  A61K47/10 ,  C07D401/14 ,  C12Y304/21

摘要： Compound represented by formula 1: or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: R1 is hydrogen, tert-butoxycarbonyl, where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (←) indicate the position of substituents attachment; R2 is hydrogen, halogen, or C1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (←) indicate the position of substituents attachment.

摘要翻译： 由式1表示的化合物或其药学上可接受的盐，水合物，结晶形式或立体异构体，其中：其中R11是任选取代的C 1 -C 6烷基，任选取代的C 3 -C 6环烷基或任选取代的C 1 -C 6烷氧基，箭头（< - ）表示取代基连接的位置; R2是氢，卤素或C1-C4烷基; R 3是任选取代的芳基，任选取代的芳氧基，任选取代的芳基硫烷基，任选取代的芳基氨基或任选取代的氮杂芳基; 其中R 41是任选取代的C 1 -C 6烷基，任选取代的C 3 -C 6环烷基或任选取代的C 1 -C 6烷氧基; X是丁-1,3-二亚炔基或1,4-亚苯基; 箭头（< - ）表示取代基连接的位置。

公开(公告)号：US09381201B2

公开(公告)日：2016-07-05

申请号：US14354141

申请日：2012-10-25

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

发明人： Alexandre Vasilievich Ivachtchenko ,  Sergey Yevgenievich Tkachenko ,  Vadim Vasilievich Bichko

IPC分类号： A61K31/5383 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/395 ,  A61K9/00 ,  A61K45/06 ,  A61K9/20 ,  A61K9/48 ,  A61K31/513

CPC分类号： A61K31/5383 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/4858 ,  A61K31/395 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to pharmacology and medicine, more particularly to novel pharmaceutical compositions and pharmaceutical kits for treating bacterial infections, and to novel method for treating diseases caused by bacterial infections including tuberculosis. The pharmaceutical composition is disclosed comprising Rifamycin and interferon inducer in pharmacologically effective doses, and also pharmaceutical kit for treating diseases caused by bacterial and healthcare acquired infections, comprising pharmacologically effective doses of Rifamycin in the form of a tablet, a capsule or an injection, interferon inducer in the form of a tablet, a capsule or an injection, and instruction for administration of the components of this pharmaceutical kit.

摘要翻译： 本发明涉及药理学和药物，更具体地涉及用于治疗细菌感染的新型药物组合物和药物试剂，以及用于治疗由细菌感染（包括结核病）引起的疾病的新方法。 公开了药物组合物，其包含药理学有效剂量的利福霉素和干扰素诱导剂，以及用于治疗由细菌和保健性获得性感染引起的疾病的药物试剂盒，其包含片剂，胶囊或注射剂，干扰素形式的药理学有效剂量的利多霉素 片剂，胶囊或注射剂形式的诱导剂和用于给药该药物试剂盒组分的说明书。

公开(公告)号：US20140303155A1

公开(公告)日：2014-10-09

申请号：US14354141

申请日：2012-10-25

申请人： Alexandre Vasilievich Ivachtchenko ,  Andrey Alexandrovich Ivashchenko ,  Nikolay Filippovich Savchuk

发明人： Alexandre Vasilievich Ivachtchenko ,  Sergey Yevgenievich Tkachenko ,  Vadim Vasilievich Bichko

IPC分类号： A61K31/5383 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496

CPC分类号： A61K31/5383 ,  A61K9/0019 ,  A61K9/2018 ,  A61K9/4858 ,  A61K31/395 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/513 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to pharmacology and medicine, more particularly to novel pharmaceutical compositions and pharmaceutical kits for treating bacterial infections, and to novel method for treating diseases caused by bacterial infections including tuberculosis.The pharmaceutical composition is disclosed comprising Rifamycin and interferon inducer in pharmacologically effective doses, and also pharmaceutical kit for treating diseases caused by bacterial and healthcare acquired infections, comprising pharmacologically effective doses of Rifamycin in the form of a tablet, a capsule or an injection, interferon inducer in the form of a tablet, a capsule or an injection, and instruction for administration of the components of this pharmaceutical kit.

摘要翻译： 本发明涉及药理学和药物，更具体地涉及用于治疗细菌感染的新型药物组合物和药物试剂，以及用于治疗由细菌感染（包括结核病）引起的疾病的新方法。 公开了药物组合物，其包含药理学有效剂量的利福霉素和干扰素诱导剂，以及用于治疗由细菌和保健性获得性感染引起的疾病的药物试剂盒，其包含片剂，胶囊或注射剂，干扰素形式的药理学有效剂量的利多霉素 片剂，胶囊或注射剂形式的诱导剂和用于给药该药物试剂盒组分的说明书。